Matthew Griffin | Bloomberg News (TNS)
GSK Plc’s experimental gonorrhea vaccine got fast-track designation from U.S. regulators, putting the shot in position to become the first preventive for a common, often-undetected infection that’s gaining resistance to treatment.
The Food and Drug Administration status makes the drug eligible for a sped-up approval process, if an ongoing midstage trial shows it’s effective, the company said Tuesday. GSK learned of its status in April and plans to move the vaccine to final-stage testing in 2026, said Giulia Giordano, vaccine development leader for the project.
In 2020, some 82 million people worldwide caught gonorrhea, a sexually transmitted infection that can lead to complications including infertility. While some patients show early symptoms, such as pain or urethral discharge in men or vaginal discharge in women, many cases may be missed even as the disease does long-term damage.
The situation has been exacerbated by gonorrhea’s growing resistance to most antibiotics, and the one that most doctors rely on, ceftriaxone, is now under threat as well. That’s left experts clamoring for a vaccine.
“We’re very concerned that we are staring straight in the face the prospect of untreatable gonorrhea,” said Jeffrey Klausner, who directed sexually transmitted disease prevention and control for the San Francisco Department of Public Health from 1998 to 2009.
The threat of gonorrhea, along with other sexually transmitted diseases like syphilis and chlamydia, is on the rise around the world. Cases hit a record high in England last year. In the U.S., the rate of reported infections more than doubled between 2009 and 2021.
While older antibiotics like penicillin were once effective, according to the World Health Organization, all gonorrhea strains are now impervious to one or more of the standard drugs. Ceftriaxone, meanwhile, must be taken by injection, and its days may be numbered.
“There is this huge unmet…
Read the full article here
